The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...